PUT - SPRINTER OPEN END - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 12:54:12 18/06/2024 BST | ||
| 11.18 EUR | -0.71% |
|
| Current month | -37.27% | ||
| 1 month | -48.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 11.18 | -0.71% |
| 17/06/24 | 11.26 | -7.25% |
| 14/06/24 | 12.14 | -0.65% |
| 13/06/24 | 12.22 | -7.91% |
| 12/06/24 | 13.27 | -3.21% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 12:54 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JJ8 |
| ISIN | DE000VD1JJ87 |
| Date issued | 05/03/2024 |
| Strike | 1,007 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 20.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.84 € |
|---|---|
| Lowest since issue | 11.05 € |
| Spread | 0.21 € |
| Spread % | 1.84% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
885
USD
Average target price
855.4
USD
Spread / Average Target
-3.35%
- Stock Market
- Certificates
- Certificat
